Ionis Enters $500m+ Agreement With Royalty Pharma To Help Fund Late-Stage Pipeline
Including Wholly Owned Assets
Executive Summary
The US firm has sold some of its royalty stream for the gene therapy Spinraza and cardiovascular drug candidate, pelacarsen, to Royalty Pharma for $500m upfront, which should help fund upcoming milestones for Ionis’ late-stage pipeline.